News

Latest industry coverage

All India World

Most watched

Google News

pharmaphorum

Sanofi forges new $8bn pact with Regeneron

Pharmaceutical Technology

Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity

Fierce Pharma

Asahi Kasei wraps years of global dealmaking into a single brand

European Pharmaceutical Review

Exposure rate influences microbial viability risk during pharmaceutical freeze-thaw cycling

PR Newswire

Advances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial Efficiency

PharmaShots

Oct 1, 2026, 11:30 AM

BMS Reports US FDA Approval of Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Shots: Ref: Businesswire | Image: BMS | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post BMS Reports US FDA Approval of Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) appeared first on PharmaShots.

PharmaShots

Oct 1, 2026, 10:51 AM

Q3 2026 Biopharma Review: Mega Deals, Strategic Licensing, and a Wave of FDA Innovation

Introduction The third quarter of 2026 underscored just how rapidly the biopharma landscape is being reshaped by capital, innovation, and strategic consolidation. Across July through September, the industry saw a succession of multibillion-dollar acquisitions, high-value licensing agreements, and a broad spectrum of FDA approvals spanning oncology, rare diseases, metabolic disorders, neurology, immunology, and precision diagnostics. … The post Q3 2026 Biopharma Review: Mega Deals, Strategic Licensing, and a Wave of FDA Innovation appeared first on PharmaShots.